PMID: 11918523Mar 29, 2002Paper

Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement

The Annals of Pharmacotherapy
R Chris Rathbun, Deanna R Rossi

Abstract

To examine the use of low-dose ritonavir as a pharmacokinetic enhancer for HIV protease inhibitors. Primary articles, review articles, and conference abstracts identified by MEDLINE search (1995-May 2001) and secondary sources. Low-dose ritonavir (100-200 mg) is increasingly being combined with HIV protease inhibitors to improve their effectiveness and allow less frequent dosing. An evaluation of the clinical evidence supporting this practice was conducted. Limited outcome data exist for low-dose ritonavir-based regimens in general. Although preliminary data appear promising, more clinical evidence is needed to determine the optimal dosing, long-term safety, and relative effectiveness of this approach. The role of these regimens in early therapy remains to be defined.

References

Dec 15, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·J MallolasJ M Gatell
Dec 15, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·P W HugenJ M Lange
Mar 29, 2001·The New England Journal of Medicine·S C Piscitelli, K D Gallicano

❮ Previous
Next ❯

Citations

Jul 10, 2003·The Lancet Oncology·Justin Stebbing, Mark Bower
Jun 17, 2004·Journal of Clinical Pharmacology·Kiat RuxrungthamIndravadan H Patel
Mar 15, 2005·Clinical Pharmacokinetics·Shufeng ZhouHoward L McLeod
Jan 7, 2005·Biological & Pharmaceutical Bulletin·Michiharu KageyamaKanji Takada
Oct 9, 2007·AIDS Patient Care and STDs·Mark A Wainberg, Bonaventura Clotet
Jul 1, 2008·Expert Review of Clinical Pharmacology·Kristin H Busse, Scott R Penzak
Nov 2, 2019·Expert Opinion on Drug Metabolism & Toxicology·Dario CattaneoGiuliano Rizzardini
Mar 8, 2005·Drug Metabolism Reviews·Shufeng ZhouYu-Zong Chen
Mar 26, 2008·British Journal of Clinical Pharmacology·Samantha AbelGary J Muirhead
Apr 8, 2015·Expert Review of Gastroenterology & Hepatology·Samuel W Brayer, K Rajender Reddy
Jun 13, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C L CooperD W Cameron
May 27, 2009·Expert Opinion on Drug Metabolism & Toxicology·Zhi-Wei Zhou, Shu-Feng Zhou
Nov 25, 2003·The Journal of Pharmacology and Experimental Therapeutics·C AnthonypillaiS A Thomas
Jul 1, 2008·Expert Opinion on Drug Discovery·Zhijian Lu
Dec 12, 2019·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Tyler LanmanRonald Ellis
Jul 9, 2004·Blood·Mark BowerJustin Stebbing
Feb 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark BowerChristina Thirlwell
Jan 24, 2006·American Journal of Therapeutics·Bharat Motwani, Walid Khayr
Apr 20, 2011·Expert Opinion on Drug Metabolism & Toxicology·Mona Arab-AlameddineChantal Csajka
Apr 3, 2016·HIV Medicine·M D LiedtkeR C Rathbun
Dec 29, 2020·Future Oncology·Marit Ac VermuntJos H Beijnen
Dec 7, 2007·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·P AmarilesM J Faus

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.